MedTrace Logo

A Study to Evaluate the Efficacy and Safety of Combination Treatment of Fimasartan/Atorvastatin in Patients With Essential Hypertension and Dyslipidemia

NCT03338426 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 133

Last updated 2019-11-05

No results posted yet for this study

Summary

The objective of this clinical study is to evaluate the efficacy and safety by comparing the fimasartan/atorvastatin treatment group to the fimasartan/placebo treatment group and the placebo/atorvastatin treatment group respectively at Week 8 in patients with essential hypertension and dyslipidemia.

Conditions

  • Essential Hypertension, Dyslipidemia

Interventions

DRUG

Fimasartan 120mg

Fimasartan 120mg will be administrated once daily for 8 weeks treatment period

DRUG

Atorvastatin 40mg

Atorvastatin 40mg will be administrated once daily for 8 weeks treatment period

DRUG

Placebo for Fimasartan 120mg

Placebo for Fimasartan 120mg will be administrated once daily for 8 weeks treatment period

DRUG

Placebo for Atorvastatin 40mg

Placebo for Atorvastatin 40mg will be administrated once daily for 8 weeks treatment period

Sponsors & Collaborators

  • Boryung Pharmaceutical Co., Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-15
Primary Completion
2019-04-22
Completion
2019-04-22

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03338426 on ClinicalTrials.gov